JPMorgan upgrades Aptiv to Overweight on 2025 revenue growth

JPMorgan upgraded Aptiv to Overweight from Neutral with a price target of $145, up from $123. The analyst expects the company will “benefit disproportionately” as investors increasingly begin to look out to 2025, given a combination of faster sales growth and company-specific margin drivers. Aptiv benefits disproportionately from JPMorgan’s valuation roll-forward to 2025 from 2025, given the combination of expected strong revenue growth and margin expansion, the analyst tells investors in a research note. The firm says Aptiv has had large new business wins subsequent to it establishing a 2025 revenue target at its most recent investor day in February 2.